10-KPeriod: FY2024

STRYKER CORP Annual Report, Year Ended Dec 31, 2024

Filed February 12, 2025For Securities:SYK

Summary

Stryker Corporation's 2024 10-K filing highlights a year of robust growth and strategic acquisitions, underscoring its position as a global leader in medical technologies. The company reported a 10.2% increase in net sales, reaching $22.595 billion, driven by strong performance across both its MedSurg and Neurotechnology (up 11.1%) and Orthopaedics (up 8.9%) segments. This growth was fueled by increased unit volumes and, to a lesser extent, higher pricing, demonstrating resilience in a dynamic healthcare market. The company also completed several strategic acquisitions totaling $1.628 billion, further expanding its product portfolios and market reach. Financially, Stryker maintained healthy profitability with a gross profit margin of 63.9%. However, net earnings saw a slight decrease to $2.993 billion from $3.165 billion in the prior year, partly due to significant goodwill impairments related to its Spine business, amounting to $456 million, and a $362 million loss recognized on assets held for sale within the Spinal Implants business. Despite these charges, operating income remained strong. The company continued its commitment to capital allocation, investing in acquisitions, paying $1.219 billion in dividends, and maintaining a strong liquidity position with $3.743 billion in cash, cash equivalents, and marketable securities.

Financial Highlights

51 data points
Beta

Revenue

$22.59B

63.9% Gross Margin

Net Income

$2.99B

13.2% Net Margin

EPS (Diluted)

$7.76

Total Assets

$42.97B

Cash & Equivalents

$3.65B

Free Cash Flow

$3.49B

Financial Statements
Beta
Revenue$22.59B
Cost of Revenue$8.15B
Gross Profit$14.44B
R&D Expenses$1.47B
SG&A Expenses$7.68B
Operating Expenses$10.75B
Operating Income$3.69B
Interest Expense$396.00M
Net Income$2.99B
EPS (Basic)$7.86
EPS (Diluted)$7.76
Shares Outstanding (Basic)381.00M
Shares Outstanding (Diluted)385.60M

Key Highlights

  • 1Stryker reported a 10.2% year-over-year increase in net sales, reaching $22.595 billion, indicating strong market demand and execution.
  • 2Both major segments, MedSurg and Neurotechnology (11.1% growth) and Orthopaedics (8.9% growth), contributed to the top-line expansion.
  • 3The company made significant strategic investments in acquisitions, totaling $1.628 billion, aimed at enhancing its product offerings and market presence.
  • 4Despite overall sales growth, net earnings decreased to $2.993 billion due to substantial goodwill impairments ($456 million) and a loss on assets held for sale ($362 million) within the Spine business.
  • 5Gross profit margin remained robust at 63.9%, demonstrating effective cost management and pricing power.
  • 6Stryker maintained a strong financial position with $3.743 billion in cash, cash equivalents, and marketable securities and a commitment to returning capital to shareholders through dividends ($1.219 billion paid).
  • 7The company is actively managing its product portfolio, evidenced by the reclassification and planned sale of its US Spinal Implants business.

Frequently Asked Questions

Stryker reported a 10.2% increase in net sales, reaching $22.595 billion. While gross profit increased by 10.6%, net earnings decreased by 5.4% to $2.993 billion, primarily due to significant goodwill impairments related to its Spine business and a loss on assets held for sale within the Spinal Implants business. Adjusted net earnings per diluted share grew by 15.0% to $12.19.

The MedSurg and Neurotechnology segment saw net sales increase by 11.1% to $13.518 billion, while the Orthopaedics segment's net sales grew by 8.9% to $9.077 billion. Both segments benefited from increased unit volumes and higher prices.

Stryker completed several acquisitions totaling $1.628 billion, aimed at strengthening its product portfolios in areas like Instruments, Endoscopy, Medical, Neuro Cranial, Trauma and Extremities, and Joint Replacement. Additionally, the company committed to selling certain assets within its Spinal Implants business and entered into an agreement to acquire Inari Medical, Inc. for approximately $4.9 billion.

Key risks include supply chain disruptions, inflationary pressures, pricing pressures from cost containment measures, intense competition, regulatory compliance (particularly the EU MDR), cybersecurity threats, integration risks from acquisitions, and potential impacts from geopolitical events and climate change. The company also noted goodwill impairments related to its Spine business as a significant event impacting its financial results.